AbCellera Biologics Inc. (ABCL) Stock Overview
Explore AbCellera Biologics Inc.’s financial performance, market position, analyst ratings, and future outlook.
AbCellera Biologics Inc. (ABCL)
Key Financials
Key Financials
Market Cap
3.8B
P/E Ratio
-23.04
EPS (TTM)
$-0.54
ROE
-0.17%
ABCL Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of AbCellera Biologics Inc. (NASDAQ: ABCL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, AbCellera Biologics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ABCL on the NASDAQ shows an RSI of 73.46, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $6.54 for the NASDAQ listing.
Key metrics behind AbCellera Biologics Inc.'s NASDAQ-traded stock include a P/E ratio of -23.04 and a market capitalization of 3.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ABCL on the NASDAQ.